Based on NIH | When should I see a doctor for vision problems if I have endometrial cancer?

Sudden or new vision problems can be urgent if you have endometrial cancer, especially during or after treatment with chemotherapy or immunotherapy. Seek emergency care right away for any sudden vision loss, double vision, flashes of light, a “curtain” over part of your vision, or severe eye pain even if symptoms are brief or painless. ^{[1] [2] [3]}

Red‑flag symptoms that need urgent or emergency care

• Sudden vision loss (partial or complete), in one or both eyes. Sudden vision loss is always an emergency and should be assessed immediately in an emergency department or by an ophthalmologist. ^[1]
• New or sudden double vision (diplopia). Even if it comes and goes, this can signal a serious eye or neurologic problem. ^[2]
• Flashes, new floaters, or a “shade/curtain” across vision. These may indicate retinal tear or detachment and need same‑day urgent evaluation. ^{[2] [3]}
• Severe eye pain, marked redness or swelling, or high light sensitivity with blurred vision. These can occur with treatment‑related inflammation of eye structures (for example, uveitis or keratitis) and should be assessed promptly. ^{[4] [5]}
• Rapidly worsening blurred or hazy vision, halos, or blind spots. Sudden changes can reflect serious eye or systemic conditions. ^{[3] [2]}

Why endometrial cancer treatment matters for your eyes

Many endometrial cancer regimens include platinum‑ and taxane‑based chemotherapy and, increasingly, immune checkpoint inhibitors; each can affect the eyes in different ways. Because some eye side effects can threaten sight if not treated early, it’s important to recognize symptoms and act quickly. ^[6]

Immunotherapy (e.g., dostarlimab, durvalumab)

• Immune checkpoint inhibitors can cause eye inflammation such as uveitis (inflammation inside the eye), keratitis (corneal inflammation), episcleritis, blepharitis, optic neuritis, and tear‑duct issues, which may present with eye pain, redness, light sensitivity, and blurred vision. ^[7]
• Patient‑facing guidance for regimens that include checkpoint inhibitors advises telling your care team immediately or going to the Emergency Department if you develop blurred vision, eye pain, red or swollen eyes, changes in color vision, or marked light sensitivity. ^{[4] [5]}
• A recent case described bilateral panuveitis with decreased vision after dostarlimab, improving with corticosteroids after drug interruption, highlighting the need for urgent ophthalmology evaluation when vision changes occur. ^[8]

Chemotherapy (carboplatin and paclitaxel)

• Carboplatin has rarely been linked to vision loss (sometimes loss of light and color perception), particularly at higher doses; vision often improves after stopping the drug, but immediate reporting of any eyesight changes is recommended. ^{[9] [10] [11]}
• Paclitaxel can cause ocular/visual disturbances, including keratitis, blurred vision, and rarely cystoid macular edema (CME) or optic nerve effects; new visual impairment warrants prompt eye assessment and notifying your oncology team. ^{[12] [13]}

When to call your oncology team within 24–48 hours

If symptoms are mild and not sudden or severe, you should still contact your cancer team promptly because treatment‑related eye effects can escalate:

• New or worsening blurred vision, gritty/watery or very dry eyes, light sensitivity, or color vision changes. ^{[4] [5]}
• Persistent eye redness, irritation, or discomfort. ^[4]
• Headache with visual changes (can signal treatment‑related hormone problems or optic issues) and should be reviewed. ^{[14] [15]}

Your team may coordinate same‑day or expedited ophthalmology referral, especially if you are on immunotherapy, because early steroids and targeted eye care can prevent long‑term damage. Multidisciplinary management with eye specialists is often recommended for treatment‑related ocular events in gynecologic cancers. ^[6]

Less common but important: paraneoplastic vision problems

Although rare, paraneoplastic retinopathy can occur with endometrial cancer and may cause progressive vision loss, light sensitivity, and ring‑shaped visual field defects. ^[16] Case reports describe decreased visual acuity and visual field narrowing linked to autoantibodies against retinal proteins. ^{[17] [18]} If you have unexplained, persistent visual decline not explained by treatment or common eye conditions, ask for ophthalmology and neuro‑ophthalmology evaluation. ^[16]

Practical steps you can take now

• Have a low threshold for urgent care if you notice sudden vision loss, double vision, a curtain over your vision, flashes, new floaters, or severe eye pain. ^{[1] [2] [3]}
• Tell your oncology team right away about any new eye or vision symptoms during chemotherapy or immunotherapy; bring your treatment alert card if you have one. ^{[4] [5]}
• Protect your eyes from sun and wind and use prescribed lubricating or steroid eye drops exactly as directed if given. ^{[4] [5]}
• Keep a symptom log noting onset, which eye is affected, associated pain, light sensitivity, headaches, or neurologic symptoms; this helps triage. (No citation required)
• Bring an updated medication list to eye visits; some non‑cancer medicines can also affect vision. (No citation required)

At‑a‑glance: when to seek care

Symptom	Action	Why it matters
Sudden vision loss, curtain over vision, flashes/floaters, sudden double vision, severe eye pain	Go to Emergency Department now	May signal retinal detachment, optic nerve inflammation, stroke‑like events, or severe treatment‑related inflammation; time‑sensitive for vision preservation. [1] [2] [3]
New or worsening blurred vision, color vision change, light sensitivity, red/swollen eyes	Call your oncology team within 24–48 hours for urgent triage and eye referral	Can reflect immunotherapy‑related uveitis/keratitis or chemo‑related ocular toxicity; early treatment prevents damage. [4] [5] [12] [13]
Persistent, progressive vision decline without clear cause	Request ophthalmology/neuro‑ophthalmology evaluation	Rare paraneoplastic retinopathy can occur in endometrial cancer and needs specialized testing. [16] [17] [18]
Any eyesight change while on carboplatin or paclitaxel	Notify your team promptly	Carboplatin has rare vision loss reports; paclitaxel can cause keratitis/blurred vision/CME. [9] [10] [11] [12] [13]

Bottom line

Having endometrial cancer and receiving modern treatments means eye symptoms deserve quick attention. If symptoms are sudden or severe, go to emergency care immediately; for new or persistent changes, contact your oncology team within 24–48 hours so they can arrange timely eye evaluation and protect your vision. ^{[1] [2] [3] [4] [5] [6]}